Updated Jul 16, 2026
Krop Julie has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $125K.
Julie Krop is the Chief Marketing Officer at DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing treatments for ischemic diseases. She has been involved in the company's marketing strategies but does not have significant public recognition.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | AQST | Aquestive Therapeutics, Inc. | S — Open-market sale | 25.0K | $5.02 | $125K |
| 2026-06-24 | AQST | Aquestive Therapeutics, Inc. | M — Option exercise | 25.0K | $0.71 | $18K |
Julie Krop is the Chief Marketing Officer at DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing treatments for ischemic diseases. She has been involved in the company's marketing strategies but does not have significant public recognition.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($125K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Krop Julie profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.